We right now believe we have plenty of supply to cover us through the end of the year and that's when we anticipate that DOXIL should be coming back online, according to announcements from Janssen or J&J.
We also point out that we've been working closely with Janssen on this supply purchase and they've recognized the importance of the PROCEED trial and will work with us to help us make sure we get as much stock that's available.
Second thing is the EU filing update. We continue to have good interactions and frequent interactions with the EU regulators. We have the vintafolide filing, which is EC145, ready to go.
We had some discussion recently with the EU where they have asked us to put all the filings in at one time. We were going to do them sequential but they have requested that they come in all at one time, both the imaging and the therapeutic filing.And so we'll probably have all of those go in in the fourth quarter. It's not going to delay the review period at all. It's just a request by the EU to see – so that they don't have them come in one time period and one in the other. So we're anticipating the filing will happen this year and we'll have all applications go in at one time.Ig uses another comment on Merck, we've been very happy with the interactions of Merck so far. There has been a lot of work in preparation for the EU filing as well as potential commercialization in EU.We've been transitioning the manufacturing responsibilities for – of ertarfolatide or the EC145 to Merck. We're working with them on the new indications that they will be running besides the ovarian and lung study.And we're appreciating, I guess, the immediate commercial horsepower of Merck as we work through launch plans and start to enhance KOL relationships. And so really – and also they have been spectacular as a partner to work with.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV